Endotarget

Endotarget is a biotechnology company specializing in the discovery and development of targeted protein degraders, particularly proteolysis-targeting chimeras (PROTACs). The company's research focus is primarily on oncology, with a pipeline targeting key drivers of cancer such as the estrogen receptor (ER) and Bruton's tyrosine kinase (BTK). Its lead candidate, ENT-601, is an ER degrader designed for the treatment of ER-positive breast cancer. Endotarget has operated in close association with the South Korean firm EnhancedBio and the US-based Zenopharm. Although recent reports suggest the company may be inactive or its operations have been consolidated, its pipeline remains a notable example of early-stage PROTAC development in the cancer therapeutics space.